ROG.VX - Roche Holding AG

Swiss - Swiss Delayed Price. Currency in CHF
215.65
-0.85 (-0.39%)
At close: 5:30PM CEST
Stock chart is not supported by your current browser
Previous Close216.50
Open216.00
Bid215.50 x 243000
Ask215.00 x 260500
Day's Range215.40 - 217.25
52 Week Range212.45 - 273.00
Volume1,825,021
Avg. Volume2,027,896
Market Cap184.692B
Beta0.90
PE Ratio (TTM)21.49
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield8.30 (3.82%)
Ex-Dividend Date2018-03-15
1y Target EstN/A
  • Goldman Sachs is offering a 1.6% APY savings account
    Yahoo Finance Video11 days ago

    Goldman Sachs is offering a 1.6% APY savings account

    Wall Street giant Goldman Sachs is making a big push for your savings accounts by offering an annual percentage yield of 1.6%. Yahoo Finance’s Alexis Christoforous, Julia La Roche, and Melody Hahm discuss how the bank is able to offer such a high percentage yield.

  • Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR
    Zacks18 hours ago

    Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR

    Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.

  • Roche Hemophilia Drug Gets Breakthrough Therapy Designation
    Zacks2 days ago

    Roche Hemophilia Drug Gets Breakthrough Therapy Designation

    The FDA grants Breakthrough Therapy Designation to Roche's (RHHBY) Hemlibra for treatment of people with hemophilia A without factor VIII inhibitors.

  • GSK flags pharma M&A ambitions by poaching Roche deal-maker
    Reuters3 days ago

    GSK flags pharma M&A ambitions by poaching Roche deal-maker

    GlaxoSmithKline (GSK.L) signalled its intention to boost its drug pipeline through deals on Wednesday by hiring Kevin Sin from Roche's (ROG.S) Genentech unit to lead a worldwide search for promising experimental products. Barron is also a veteran of Genentech, famous for its biotech cancer medicines.

  • Reuters3 days ago

    GSK flags pharma M&A ambitions by poaching Roche deal-maker

    GlaxoSmithKline signalled its intention to boost its drug pipeline through deals on Wednesday by hiring Kevin Sin from Roche's Genentech unit to lead a worldwide search for promising experimental products. Barron is also a veteran of Genentech, famous for its biotech cancer medicines.

  • Reuters3 days ago

    GSK grabs Roche cancer expert to lead pharma pipeline deals

    GlaxoSmithKline said on Wednesday it had hired Kevin Sin from Roche's Genentech unit to head worldwide business development for pharmaceuticals research and development. Sin, who will join GSK in San Francisco ...

  • 4,000,000 Reasons to Back China Biotech
    Bloomberg3 days ago

    4,000,000 Reasons to Back China Biotech

    With cancer rates rising, Jiangsu Hengrui has a shot at becoming the next Roche or Pfizer.

  • Reuters4 days ago

    Roche's Hemlibra gets speedy FDA review for wider use

    Roche's hemophilia A drug Hemlibra will get an accelerated review by U.S. regulators for use in a new group of patients, a key part of the Swiss drug company's plans to muscle in on turf dominated by rivals including Shire. The U.S. Food and Drug Administration granted breakthrough therapy designation to the medicine to be used in people who have not yet developed resistance to conventional treatments, called inhibitors, Roche said on Tuesday. Hemlibra is already approved for people with inhibitors, though Shire is fighting Roche in court seeking to halt expanded use of the medicine.

  • What Investors Should Know About Roche Holding AG’s (VTX:ROG) Financial Strength
    Simply Wall St.9 days ago

    What Investors Should Know About Roche Holding AG’s (VTX:ROG) Financial Strength

    Investors seeking to preserve capital in a volatile environment might consider large-cap stocks such as Roche Holding AG (SWX:ROG) a safer option. Doing business globally, large caps tend to haveRead More...

  • Incyte's Horrible News Derails a Promising Class of Cancer Drugs
    Motley Fool14 days ago

    Incyte's Horrible News Derails a Promising Class of Cancer Drugs

    The failure of an important trial casts doubt on the future of combination immunotherapy.

  • Morningstar22 days ago

    Healthcare: Values Among Drug, Biotech, and Supply Chain Firms

    Innovation, consolidation, and a mixed regulatory picture for healthcare stocks in the first- quarter.

  • Roche Hashes Out Details Of Patient Deaths In Hemophilia Drug
    Investor's Business Daily23 days ago

    Roche Hashes Out Details Of Patient Deaths In Hemophilia Drug

    Roche offered additional details Thursday on the deaths of five patients taking its potential blockbuster drug Hemlibra.

  • Reuters24 days ago

    Tokyo court rejects Shire claim against Roche haemophilia drug

    A Tokyo court has ruled that Shire's (SHP.L) claim against Swiss drugmaker Roche's (ROG.S) new Hemlibra haemophilia medicine should be dismissed, Roche's Japanese subsidiary Chugai said on Wednesday, helping to clear up legal uncertainty over the prospective blockbuster medicine. Chugai, which is 60 percent Roche-owned and which developed Hemlibra, said it expected no change to its financial prospects due to the ruling. "Tokyo District Court rendered a decision in favour of Chugai's claim," Chugai said on its website.

  • Roche Takes Aim at Bristol-Myers Squibb and Merck & Co.
    Motley Fool24 days ago

    Roche Takes Aim at Bristol-Myers Squibb and Merck & Co.

    The biopharma Goliath could soon be battling for billions of dollars in cancer drug sales.

  • Roche's Tecentriq Combo Study Meets Co-Primary Endpoint
    Zacks26 days ago

    Roche's Tecentriq Combo Study Meets Co-Primary Endpoint

    Roche's (RHHBY) phase III study, evaluating a combination of Tecentriq and Avastin plus carboplatin and paclitaxel for first line treatment of advanced lung cancer met its co-primary endpoint of overall survival.

  • The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer
    Zacks26 days ago

    The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer

    The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer

  • Reuters26 days ago

    Roche's Tecentriq cocktail notches another lung cancer success

    Roche's immunotherapy Tecentriq combined with other drugs boosted lung cancer patients' survival versus an older cocktail, the Swiss company's latest trial success as it seeks an edge on Merck and Bristol-Myers Squibb. Mixing Tecentriq with Avastin and chemotherapies carboplatin and paclitaxel boosted overall survival in first-line treatment of non-squamous non-small cell lung cancer, Roche said on Monday, compared to patients who received only Avastin plus carboplatin and paclitaxel.

  • CNBC26 days ago

    European markets higher as trade war concerns ease; Fresnillo shares rise 5%

    European markets were higher on Monday afternoon, as lingering fears of a tit-for-tat global trade war appeared to ease.

  • Pharma Stock Roundup: ABBV's Rova-T Disappoints, J&J Unit Gets Buyout Offer
    Zacks29 days ago

    Pharma Stock Roundup: ABBV's Rova-T Disappoints, J&J Unit Gets Buyout Offer

    AbbVie's key lung cancer candidate, Rova-T falls short in a phase II study, J&J gets buyout offer for its LifeScan unit from private firm, Platinum Equity.

  • Cancer Space Roundup: NVS' Tasigna & SGEN's Adcetris Label Expansions in Focus
    Zacks29 days ago

    Cancer Space Roundup: NVS' Tasigna & SGEN's Adcetris Label Expansions in Focus

    Novartis' (NVS) Tasigna and Seattle Genetics' (SGEN) Adcetris receive regulatory approvals for label expansion. Pfizer's label expansion application for Xtandi gets priority review.

  • Roche's (RHHBY) Lucentis 0.3 mg PFS Receives FDA Approval
    Zackslast month

    Roche's (RHHBY) Lucentis 0.3 mg PFS Receives FDA Approval

    Roche's (RHHBY) opthalmology drug, Lucentis 0.3 mg prefilled syringe (PFS) is a new method of administering medicine for all forms of diabetic retinopathy.

  • Britain's use of copycat biotech drugs takes off while U.S. lags
    Reuterslast month

    Britain's use of copycat biotech drugs takes off while U.S. lags

    Cut-price copies of an expensive Roche (ROG.S) biotech drug for blood cancer have taken 80 percent of the British market since launching last year, saving the healthcare system 80 million pounds a year, experts said on Wednesday. The rapid adoption of two so-called biosimilar forms of rituximab from Celltrion and Novartis (NOVN.S) has been accompanied by discounts of 50-60 percent as the National Health Service (NHS) has used tenders to bring down costs. The situation contrasts sharply with the United States, where regulators have lagged Europe in approving biosimilars while a complex system of rebates offered to insurers by original-brand drugmakers has created barriers to use.

  • Reuterslast month

    Britain's use of copycat biotech drugs takes off while U.S. lags

    Cut-price copies of an expensive Roche biotech drug for blood cancer have taken 80 percent of the British market since launching last year, saving the healthcare system 80 million pounds ($113 million) a year, experts said on Wednesday. The rapid adoption of two so-called biosimilar forms of rituximab from Celltrion and Novartis has been accompanied by discounts of 50-60 percent as the National Health Service (NHS) has used tenders to bring down costs. The situation contrasts sharply with the United States, where regulators have lagged Europe in approving biosimilars while a complex system of rebates offered to insurers by original-brand drugmakers has created barriers to use.

  • Roche Tecentriq Phase III Combo Study Meets Primary Endpoint
    Zackslast month

    Roche Tecentriq Phase III Combo Study Meets Primary Endpoint

    Roche (RHHBY) announces that the combination study of Tecentriq plus chemotherapy meets its co-primary endpoint of progression-free survival.

  • Reuterslast month

    Roche's Tecentriq notches third cancer cocktail trial win

    Roche's immunotherapy Tecentriq on Tuesday racked up a third trial win in combination with other cancer drugs, a boost for the Swiss drugmaker as it seeks to muscle in on space dominated by Merck and Bristol-Myers Squibb. A late-stage study, called IMpower131, demonstrated Tecentriq mixed with chemotherapies carboplatin and Abraxane cut risk of disease worsening or death (PFS), compared with chemotherapy alone, in first-line treatment of patients with advanced squamous non-small cell lung cancer.